Stocktoria
Decoy Therapeutics Inc. DCOY
Decoy Therapeutics Inc. (DCOY) earns a Piotroski F-score of 3/9 (weak financial health). It pays a dividend yielding 4.55% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DCOY | Decoy Therapeutics Inc. | 3/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
FAQ
Is DCOY financially healthy?
Decoy Therapeutics Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does DCOY pay a dividend, and is it safe?
Yes. Decoy Therapeutics Inc. pays a dividend yielding about 4.55% with a None payout ratio, rated “no dividend” for safety.
How profitable is DCOY?
In FY2025, Decoy Therapeutics Inc. had a return on equity of -212.6%.
What is the analyst price target for DCOY?
The average Wall-Street price target for Decoy Therapeutics Inc. is $30.00, about 733.3% above the recent price, from 1 analysts.
Is DCOY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Decoy Therapeutics Inc.: a Piotroski F-score of 3/9, a dividend yield of 4.55%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.